Search Medical Condition
Please enter condition
Please choose location from dropdown

Focal Segmental Glomerulosclerosis Clinical Trials

A listing of Focal Segmental Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (25) clinical trials

In this study Retrophin is studying an investigational drug called Sparsentan for treatment of patients with FSGS. The trial is being conducted to collect information about the possible effects of Sparsentan to treat protein loss in patients with FSGS, as well as other positive and negative effects of the medication.

Phase

Open-label, 24-week, multicenter, exploratory cohort study of VCS - To assess the efficacy of voclosporin (VCS) in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). - To assess the safety and tolerability of VCS over 24 weeks in subjects ...

Phase

People with focal segmental glomerulosclerosis are asked to participate in a research study being conducted by New York University School of Medicine.  

Phase N/A

People with primary focal segmental glomerulosclerosis are asked to participate in a research study being conducted by Montefiore Medical Center.

Genetic Causes of FSGS Nephrotic Syndrome or Kidney Failure

The investigators welcome anyone (with or without a family history) with unexplained, non syndromic FSGS, nephrotic syndrome, or proteinuria to join the study. Participation involves a saliva (or blood if it is preferable) sample and urine sample (if applicable). There is no cost to participate and the study can be ...

Phase N/A

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

This is a prospective study enrolling renal transplant recipients with the primary native kidney disease of FSGS. Primary endpoint is rate of recurrence of FSGS as seen in renal transplant biopsies and in rate of proteinuria. Secondary endpoint is renal function after transplantation The target subject number is 20 patients ...

Phase

A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

Phase N/A

Valproic Acid for Idiopathic Nephrotic Syndrome

Idiopathic MCD to treat diseases with a considerable associated morbidity and mortality. Current treatment options are limited, have limited efficacy and a considerable side effect profile. Recent findings in a murine model suggest that VPA treatment in an early phase of renal disease could halt or even prevent the development ...

Phase

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

FSGS and diabetic nephropathy may have common pathogenic mechanisms, that are mediated by intraglomerular hypertension, leading to hyperfiltration and proteinuria. Given that SGLT2i corrects early hemodynamic abnormalities in patients with diabetes, our aim is to determine if a similar benefit may extend to patients with FSGS. Based on previous experimental ...

Phase

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Liposorber LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve ...

Phase N/A